NES ZIONA, Israel--(AABB Annual Meeting & CTTXPO 2012, held at Boston on October 6-9, 2012, and two were presented in the DGTI Annual Congress held at Graz, Austria in September. In addition, two studies were recently published in the distinguished, peer-reviewed journals Transfusion and the Journal of Maternal-Fetal and Neonatal Medicine. All studies conclude that OrSense's non-invasive Hb monitor is reliable, accurate, easy to use and favorably accepted by both staff and subjects.)--OrSense Ltd., developer of monitors for non-invasive measurements of various blood parameters, reports today that its non-invasive Hemoglobin (Hb) monitor was the topic of multiple recent studies highlighting the clinical value of the device. Five studies, from various countries around the world, will be presented as posters at the
“in our opinion, procuring a better experience for blood donors may undisputedly facilitate repetition.”
The studies were conducted independently by groups from Central Institute for Blood Transfusion and Immunology, Innsbruck, Austria; State University of Campinas, Brazil; the Madrid Red Cross, Spain; Haema AG, Leipzig, and Deutsche Gesellschaft für Humanplasma Krefeld, both from Germany; Korea Yonsei University and Hanmaum Blood Center; Assaf Harofe Hospital, Israel; and Rabin Medical Center, Israel. Most of the studies were conducted in order to assess OrSense's non-invasive Hb monitor for pre-screening blood donors for anemia. The studies conclude that OrSense's device is comparable to invasive, point-of-care Hb monitoring solutions in terms of accuracy and reliability, and is superior to invasive solutions since it reduces risk of infection and eliminates the need for painful finger pricking.
According to the study by the group of Dr. Vagner Castro from the University of Campinas, Brazil, published in Transfusion (Pinto et. al. July 2012) the results obtained suggest that the OrSense monitor is more precise than the prevalent invasive point-of-care device in preventing anemic donors from donating. In addition, the study performed by the Spanish group, led by Dr. Emma Castro, from the Spanish Red Cross Transfusion Center in Madrid, assessed for the first time the impact of the non-invasive Hb monitoring experience on both staff and subjects in a blood bank facility. The researchers suggested that "in our opinion, procuring a better experience for blood donors may undisputedly facilitate repetition."
Lior Maayan, CEO of OrSense, said, "Our revolutionary technology ushers diagnostics into a new era of non-invasive monitoring of various blood parameters. In particular, our non-invasive Hb monitor is unique in offering accurate, non-invasive measurements of this important parameter. Concerning blood banks, pre-donation Hb and anemia screening is vital for protecting the health of potential blood donors and is the most common reason for disqualifying donors. It is therefore imperative to be able to screen donors for anemia safely, quickly and reliably. The impressive body of work that was recently published regarding our non-invasive solution shows unequivocally that our device not only offers this possibility but also eliminates the need for painful finger pricking as well as biologically hazardous equipment and waste. In addition, these studies highlight the fact that our non-invasive device has the potential to increase first time and repeat blood donations."
OrSense will launch Glasswing™, its next-generation, wireless, non-invasive hemoglobin (Hb) measurement system for anemia monitoring, hemorrhage detection and pre-donation, during the AABB meeting later this week.
Non Invasive Hemoglobin Measurement
OrSense’s non-invasive Hb measurement has many advantages including the prevention of pain and potential transmission of infectious diseases, a reduced need for trained personnel, short measurement time, and the absence of bio-hazardous waste. It offers a unique, breakthrough, non-invasive solution for accurate and quick Hb measurements. The portable, wireless device operates via rechargeable batteries using a ring-shaped sensor that is fitted on the donor's finger and applies pressure, temporarily occluding local blood flow. During the occlusion, optical elements in the sensor perform a sensitive measurement of the light transmitted through the finger. This technology, called SpectOLight™, provides a quick, accurate and painless measurement of the donor's blood constituents, while greatly improving donors' comfort, eliminating infection risk, and providing the medical staff with accurate readings and immediate results.
The device has received CE and CDN approvals. It was tested on over 8,000 patients and blood donors at 20 sites in the U.S., Europe and South Africa exhibiting comparable accuracy to invasive POC solutions while also demonstrating a strong safety profile, ease of use and substantial cost reduction. The system is based on OrSense's proprietary SpectOLight™ technology, which uses a non-invasive optical measurement platform combined with a ring-shaped pneumatic probe that fits on the finger.
In July 2012, OrSense introduced Glasswing™, its next-generation, wireless, non-invasive Hb measurement system for anemia monitoring, hemorrhage detection and pre-donation screening. Glasswing offers a unique, breakthrough non-invasive solution for accurate continuous and spot Hb measurements. The new portable, wireless system enables on-line storage and download of data, real-time communication with electronic medical records in the hospital or blood donation centers as well as with other digital data devices and printers. The device is well suited for use in a variety of clinical environments, including perioperative and critical care, emergency medicine, blood donation facilities, women’s health, primary care physician’s office and homecare. Glasswing™ is pending FDA 510(k) clearance.
OrSense is a medical device company developing and marketing non-invasive monitoring systems for measurements of hemoglobin, oxygen saturation, glucose and other blood parameters. OrSense’s CE approved non-invasive hemoglobin monitor is available in 55 countries world-wide, and has been successfully installed in multiple environments including hospitals, physician offices, blood donation facilities, as well as used for various applications including public screening, women health and homecare. In addition, the Company's FDA cleared NBM 200MP is a non-invasive blood oximetry monitor for use in hospitals. OrSense's products are based on its proprietary Occlusion Spectroscopy technology, which overcomes key obstacles that hinder the performance of competing approaches. Investors in the Company include Israel Health Care Ventures and STAR Ventures. For additional information, please visit OrSense’s website at www.orsense.com.